hVIVO PLC Broker change (8647Y)
2024年1月8日 - 4:00PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMHVO
RNS Number : 8647Y
hVIVO PLC
08 January 2024
hVIVO plc
("hVIVO" or the "Company")
Appointment of Nominated Adviser and Joint Broker
hVIVO plc (AIM & Euronext: HVO) , the world leader in
testing infectious and respiratory disease products using human
challenge clinical trials, announces the appointment of Cavendish
Capital Markets Limited as Nominated Adviser and Joint Broker and
Peel Hunt LLP as Joint Broker with immediate effect.
For further information please contact:
hVIVO plc +44 (0) 20 7756 1300
Yamin 'Mo' Khan, Chief Executive
Officer
Stephen Pinkerton, Chief Financial
Officer
Cavendish Capital Markets Limited (Nominated
Adviser and Joint Broker) +44 (0) 20 7220 0500
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet
Ward
P eel Hunt L LP (Joint Broker) +44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Euronext Growth Adviser and Joint Broker) +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) +44 (0) 20 7933 8780 or hvivo@walbrookpr.com
Stephanie Cuthbert / Phillip +44 (0) 7796 794 663 / +44 (0) 7867 984
Marriage / 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
About hVIVO
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly
growing specialist contract research organisation (CRO) and the
world leader in testing infectious and respiratory disease vaccines
and therapeutics using human challenge clinical trials. The Group
provides end-to-end early clinical development services to its
large, established and growing repeat client base, which includes
four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique
portfolio of 11 human challenge models, with a number of new models
under development, to test a broad range of infectious and
respiratory disease products. The Company has world class challenge
agent manufacturing, specialist drug development and clinical
consultancy services via its Venn Life Sciences brand, and a lab
offering via its hLAB brand, which includes virology, immunology
biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and
clinical trial site services.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
clinic in Plumbers Row. To recruit volunteers / patients for its
studies, the Company leverages its unique clinical trial
recruitment capability via its FluCamp volunteer screening
facilities in London and Manchester.
Existing Board - AIM Rule 17 Disclosure
The Company announces the following additional director
disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g)
of the AIM Rules for Companies.
Elaine Sullivan
In addition to the disclosures made in Elaine Sullivan's
announcement of appointment on 24 November 2020, the following
directorships are disclosed:
Company Current, or last 5 years
Carrick Therapeutics Limited Directorship held in last 5 years,
at time of appointment to hVIVO
-----------------------------------
Brendan Buckley
The following directorships were disclosed incorrectly in the
Company's Admission Document dated 9 December 2019:
Company Disclosure
Irish Platform for Patients' Organisations, Directorship held more than 5 years
Science and Industry Company Limited prior to publication of the Admission
Document and therefore should not
have been disclosed in the Admission
Document
---------------------------------------
Cathal Friel
In addition to the disclosures made in the Admission Document
dated 9 December 2019, the following directorships are
disclosed:
Company Current, or last 5 years
Amryt Pharma Holdings Limited Directorship held in last 5 years
at time of Admission Document publication
-------------------------------------------
Venn Life Sciences Limited Current directorship at the time
Venn Life Sciences (Germany) GmbH of Admission Document publication
Venn Life Sciences (Ireland) Limited
Venn Life Sciences (NI) Limited
Venn Life Sciences (Australia) Pty
Ltd
Venn Life Sciences Inc.
Venn Life Sciences Legal Representation
B.V
Venn Life Sciences ED B.V.
Venn Life Sciences (France) SAS
Venn Life Sciences B.V.
-------------------------------------------
The following directorships were disclosed incorrectly in the
Company's Admission Document dated 9 December 2019:
Company Current, or last 5 years
Amryt Pharma plc Incorrectly disclosed as a directorship
--------------------------------------------
Fastnet Hydrocarbons Limited Directorship held in last 5 years
Raglan Natural Resources Limited at time of Admission Document publication.
These directorships were disclosed
as current directorships in the Admission
Document
--------------------------------------------
Fitzwilliam Place Capital Limited Directorship held more than 5 years
prior to Admission Document publication
and therefore should not have been
disclosed in the Admission Document
--------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPQKABQBBKDCDK
(END) Dow Jones Newswires
January 08, 2024 02:00 ET (07:00 GMT)
hVIVO (AQSE:HVO.GB)
過去 株価チャート
から 11 2024 まで 12 2024
hVIVO (AQSE:HVO.GB)
過去 株価チャート
から 12 2023 まで 12 2024
